Clinical Focus ›› 2025, Vol. 40 ›› Issue (8): 698-704.doi: 10.3969/j.issn.1004-583X.2025.08.005
Previous Articles Next Articles
Zhuang Huicui1, Guo Hao2(), Li Xian2, Cui Dongsheng2
Received:
2025-04-24
Online:
2025-08-20
Published:
2025-09-05
Contact:
Guo Hao
E-mail:guohao1974@163.com
CLC Number:
Zhuang Huicui, Guo Hao, Li Xian, Cui Dongsheng. Analysis of prognostic risk factors and predictive value in patients with bloodstream infection complicated with sepsis[J]. Clinical Focus, 2025, 40(8): 698-704.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.08.005
项目 | 例数(例) | 百分比(%) |
---|---|---|
性别 | ||
男 | 92 | 56.8 |
女 | 70 | 43.2 |
年龄(岁) | ||
<60 | 45 | 27.8 |
60~74 | 79 | 48.8 |
≥75 | 38 | 23.4 |
28 d预后情况 | ||
死亡 | 91 | 56.2 |
存活 | 71 | 43.8 |
Tab.1 General information of sepsis patients with BSI (n=162)
项目 | 例数(例) | 百分比(%) |
---|---|---|
性别 | ||
男 | 92 | 56.8 |
女 | 70 | 43.2 |
年龄(岁) | ||
<60 | 45 | 27.8 |
60~74 | 79 | 48.8 |
≥75 | 38 | 23.4 |
28 d预后情况 | ||
死亡 | 91 | 56.2 |
存活 | 71 | 43.8 |
组别 | 例数 | 性别[例(%)] | 年龄 (岁) | 社区获得性 [例(%)] | 非ICU医院 获得性 [例(%)] | ICU获得性 [例(%)] | 评分(分) | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | SOFA 评分 | APACHEⅡ 评分 | mNUTRIC 评分 | SIC 评分 | ||||||||||||||||||||||||||
死亡组 | 91 | 55(60.4) | 36(39.6) | 71(63, 76) | 45(49.5) | 19(20.9) | 27(29.7) | 13(11, 15) | 25(20, 31) | 7(6, 8) | 4(3, 6) | ||||||||||||||||||||
存活组 | 71 | 37(52.1) | 34(47.9) | 63(50, 71) | 50(70.4) | 11(15.5) | 10(14.1) | 8(6, 11) | 18(14, 22) | 5(3, 6) | 4(3, 5) | ||||||||||||||||||||
t/Z/χ2值 | 1.127 | -3.384 | 7.233 | 0.767 | 5.497 | -7.157 | -6.523 | -5.700 | -2.724 | ||||||||||||||||||||||
P值 | 0.288 | 0.001 | 0.007 | 0.381 | 0.019 | 0.000 | 0.000 | 0.000 | 0.006 | ||||||||||||||||||||||
组别 | 治疗情况[例(%)] | 生命体征 | |||||||||||||||||||||||||||||
机械通气 | 深静脉置管 | 肾脏替代治疗 | 血管活性药物 使用>24 h | MAP(mmHg) | HR(次/min) | ||||||||||||||||||||||||||
死亡组 | 82(90.1) | 79(86.8) | 37(40.7) | 76(83.5) | 70(58, 77) | 127.8±25.5 | |||||||||||||||||||||||||
存活组 | 48(67.6) | 39(54.9) | 7(9.9) | 25(35.2) | 73(66, 80) | 116.2±25.0 | |||||||||||||||||||||||||
t/Z/χ2值 | 12.664 | 20.367 | 19.006 | 39.397 | -2.415 | -2.892 | |||||||||||||||||||||||||
P值 | 0.000 | 0.000 | 0.000 | 0.000 | 0.014 | 0.004 | |||||||||||||||||||||||||
组别 | 实验室资料 | ||||||||||||||||||||||||||||||
P/F (mmHg) | WBC (×109/L) | NEUT% | Neut (×109/L) | Lymph (×109/L) | NLR | Lac (mmol/L) | |||||||||||||||||||||||||
死亡组 | 156(105, 208) | 14.6(10.2, 22.4) | 90.8(84.4, 94.2) | 12.5(8.7, 20.9) | 0.5(0.3, 0.8) | 17(10, 37) | 3.9(2.2, 9.2) | ||||||||||||||||||||||||
存活组 | 195(160, 270) | 17.5(11.7, 25.0) | 92.5(89.1, 95.2) | 16.3(10.5, 22.7) | 0.6(0.4, 0.8) | 26.5(15, 40) | 2.9(1.9, 4.9) | ||||||||||||||||||||||||
t/Z/χ2值 | -3.717 | -2.079 | 1.943 | -1.944 | -0.756 | 1.896 | -2.306 | ||||||||||||||||||||||||
P值 | 0.000 | 0.038 | 0.052 | 0.052 | 0.450 | 0.058 | 0.021 | ||||||||||||||||||||||||
组别 | 实验室资料 | ||||||||||||||||||||||||||||||
PCT(μg/L) | PLT(×109/L) | D-Dimer(mg/L) | Alb(g/L) | TBil(μmol/L) | Cr(μmol/L) | ||||||||||||||||||||||||||
死亡组 | 19.7(4.6, 86.3) | 108(48, 176) | 8.3(4.7, 18.2) | 25.9±5.4 | 22.8(12.8, 41.5) | 156(94.2, 262.1) | |||||||||||||||||||||||||
存活组 | 17.3(2.8, 51) | 134(68, 204) | 6(2.9, 13.8) | 25.8±6.3 | 21.9(11, 37.7) | 91.4(62.7, 147.8) | |||||||||||||||||||||||||
t/Z/χ2值 | -0.999 | -1.965 | -2.225 | -0.143 | -0.439 | -4.159 | |||||||||||||||||||||||||
P值 | 0.318 | 0.049 | 0.026 | 0.889 | 0.661 | 0.000 |
Tab. 2 Univariate analysis of the prognosis of sepsis patients with BSI
组别 | 例数 | 性别[例(%)] | 年龄 (岁) | 社区获得性 [例(%)] | 非ICU医院 获得性 [例(%)] | ICU获得性 [例(%)] | 评分(分) | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | SOFA 评分 | APACHEⅡ 评分 | mNUTRIC 评分 | SIC 评分 | ||||||||||||||||||||||||||
死亡组 | 91 | 55(60.4) | 36(39.6) | 71(63, 76) | 45(49.5) | 19(20.9) | 27(29.7) | 13(11, 15) | 25(20, 31) | 7(6, 8) | 4(3, 6) | ||||||||||||||||||||
存活组 | 71 | 37(52.1) | 34(47.9) | 63(50, 71) | 50(70.4) | 11(15.5) | 10(14.1) | 8(6, 11) | 18(14, 22) | 5(3, 6) | 4(3, 5) | ||||||||||||||||||||
t/Z/χ2值 | 1.127 | -3.384 | 7.233 | 0.767 | 5.497 | -7.157 | -6.523 | -5.700 | -2.724 | ||||||||||||||||||||||
P值 | 0.288 | 0.001 | 0.007 | 0.381 | 0.019 | 0.000 | 0.000 | 0.000 | 0.006 | ||||||||||||||||||||||
组别 | 治疗情况[例(%)] | 生命体征 | |||||||||||||||||||||||||||||
机械通气 | 深静脉置管 | 肾脏替代治疗 | 血管活性药物 使用>24 h | MAP(mmHg) | HR(次/min) | ||||||||||||||||||||||||||
死亡组 | 82(90.1) | 79(86.8) | 37(40.7) | 76(83.5) | 70(58, 77) | 127.8±25.5 | |||||||||||||||||||||||||
存活组 | 48(67.6) | 39(54.9) | 7(9.9) | 25(35.2) | 73(66, 80) | 116.2±25.0 | |||||||||||||||||||||||||
t/Z/χ2值 | 12.664 | 20.367 | 19.006 | 39.397 | -2.415 | -2.892 | |||||||||||||||||||||||||
P值 | 0.000 | 0.000 | 0.000 | 0.000 | 0.014 | 0.004 | |||||||||||||||||||||||||
组别 | 实验室资料 | ||||||||||||||||||||||||||||||
P/F (mmHg) | WBC (×109/L) | NEUT% | Neut (×109/L) | Lymph (×109/L) | NLR | Lac (mmol/L) | |||||||||||||||||||||||||
死亡组 | 156(105, 208) | 14.6(10.2, 22.4) | 90.8(84.4, 94.2) | 12.5(8.7, 20.9) | 0.5(0.3, 0.8) | 17(10, 37) | 3.9(2.2, 9.2) | ||||||||||||||||||||||||
存活组 | 195(160, 270) | 17.5(11.7, 25.0) | 92.5(89.1, 95.2) | 16.3(10.5, 22.7) | 0.6(0.4, 0.8) | 26.5(15, 40) | 2.9(1.9, 4.9) | ||||||||||||||||||||||||
t/Z/χ2值 | -3.717 | -2.079 | 1.943 | -1.944 | -0.756 | 1.896 | -2.306 | ||||||||||||||||||||||||
P值 | 0.000 | 0.038 | 0.052 | 0.052 | 0.450 | 0.058 | 0.021 | ||||||||||||||||||||||||
组别 | 实验室资料 | ||||||||||||||||||||||||||||||
PCT(μg/L) | PLT(×109/L) | D-Dimer(mg/L) | Alb(g/L) | TBil(μmol/L) | Cr(μmol/L) | ||||||||||||||||||||||||||
死亡组 | 19.7(4.6, 86.3) | 108(48, 176) | 8.3(4.7, 18.2) | 25.9±5.4 | 22.8(12.8, 41.5) | 156(94.2, 262.1) | |||||||||||||||||||||||||
存活组 | 17.3(2.8, 51) | 134(68, 204) | 6(2.9, 13.8) | 25.8±6.3 | 21.9(11, 37.7) | 91.4(62.7, 147.8) | |||||||||||||||||||||||||
t/Z/χ2值 | -0.999 | -1.965 | -2.225 | -0.143 | -0.439 | -4.159 | |||||||||||||||||||||||||
P值 | 0.318 | 0.049 | 0.026 | 0.889 | 0.661 | 0.000 |
指标 | 回归系数 | 标准误 | Wald χ2值 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
年龄 | 0.067 | 0.025 | 7.442 | 0.006 | 1.070 | 1.019 | 1.123 |
SOFA评分 | 0.263 | 0.133 | 3.889 | 0.049 | 1.301 | 1.002 | 1.689 |
APACHEⅡ评分 | 0.164 | 0.082 | 3.973 | 0.046 | 1.179 | 1.003 | 1.385 |
mNUTRIC评分 | 0.122 | 0.286 | 6.074 | 0.014 | 1.105 | 1.007 | 1.206 |
P/F | -0.006 | 0.003 | 4.046 | 0.044 | 0.994 | 0.989 | 1.000 |
WBC | -0.062 | 0.024 | 6.862 | 0.009 | 0.940 | 0.897 | 0.984 |
使用血管活性药物>24 h | 1.417 | 0.581 | 5.952 | 0.015 | 4.125 | 1.321 | 12.878 |
Tab.3 Multivariate logistic analysis of 28-day prognosis in sepsis patients with BSI
指标 | 回归系数 | 标准误 | Wald χ2值 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
年龄 | 0.067 | 0.025 | 7.442 | 0.006 | 1.070 | 1.019 | 1.123 |
SOFA评分 | 0.263 | 0.133 | 3.889 | 0.049 | 1.301 | 1.002 | 1.689 |
APACHEⅡ评分 | 0.164 | 0.082 | 3.973 | 0.046 | 1.179 | 1.003 | 1.385 |
mNUTRIC评分 | 0.122 | 0.286 | 6.074 | 0.014 | 1.105 | 1.007 | 1.206 |
P/F | -0.006 | 0.003 | 4.046 | 0.044 | 0.994 | 0.989 | 1.000 |
WBC | -0.062 | 0.024 | 6.862 | 0.009 | 0.940 | 0.897 | 0.984 |
使用血管活性药物>24 h | 1.417 | 0.581 | 5.952 | 0.015 | 4.125 | 1.321 | 12.878 |
预测项目 | AUC | P值 | 95%CI | 敏感度 | 特异度 | 约登指数 | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
年龄 | 0.655 | 0.001 | 0.570 | 0.741 | 0.615 | 0.676 | 67.50 |
SOFA评分 | 0.827 | 0.000 | 0.765 | 0.889 | 0.890 | 0.577 | 9.50 |
APACHEⅡ评分 | 0.799 | 0.000 | 0.733 | 0.865 | 0.604 | 0.845 | 23.50 |
mNUTRIC评分 | 0.758 | 0.000 | 0.684 | 0.832 | 0.769 | 0.662 | 5.50 |
P/F | 0.330 | 0.000 | 0.248 | 0.412 | 0.582 | 0.127 | 133.50 |
WBC | 0.405 | 0.038 | 0.318 | 0.492 | 0.396 | 0.394 | 16.03 |
使用血管活性药物>24 h | 0.742 | 0.000 | 0.662 | 0.821 | 0.835 | 0.648 | - |
Tab.4 Predictive value of independent influencing factors for 28-day prognosis in sepsis patients with BSI
预测项目 | AUC | P值 | 95%CI | 敏感度 | 特异度 | 约登指数 | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
年龄 | 0.655 | 0.001 | 0.570 | 0.741 | 0.615 | 0.676 | 67.50 |
SOFA评分 | 0.827 | 0.000 | 0.765 | 0.889 | 0.890 | 0.577 | 9.50 |
APACHEⅡ评分 | 0.799 | 0.000 | 0.733 | 0.865 | 0.604 | 0.845 | 23.50 |
mNUTRIC评分 | 0.758 | 0.000 | 0.684 | 0.832 | 0.769 | 0.662 | 5.50 |
P/F | 0.330 | 0.000 | 0.248 | 0.412 | 0.582 | 0.127 | 133.50 |
WBC | 0.405 | 0.038 | 0.318 | 0.492 | 0.396 | 0.394 | 16.03 |
使用血管活性药物>24 h | 0.742 | 0.000 | 0.662 | 0.821 | 0.835 | 0.648 | - |
[1] | Zahar JR, Timsit JF, Garrouste-Orgeas M, et al. Outcomes in severe sepsis and patients with septic shock: Pathogen species and infection sites are not associated with mortality[J]. Crit Care Med, 2011, 39(8):1886-1895. |
[2] | 李雪, 赵涛, 吴嘉荔, 等. 早期降钙素、中性粒细胞百分比、血清乳酸对血流感染的脓毒症患者预后判断价值[J]. 糖尿病天地, 2019, 16(2):7-8. |
[3] | 赵磊, 盛博, 李丽娟, 等. 血流感染脓毒症患者炎症因子水平与疾病严重程度相关性研究[J]. 中华医院感染学杂志, 2015, (17):3841-3844. |
[4] | 钟敏林. 血流感染脓毒症患者的证治特点与预后相关性分析[D]. 广州: 广州中医药大学, 2022. |
[5] | Vallés J, Ferrer R. Bloodstream infection in the ICU[J]. Infect Dis Clin North Am, 2009, 23(3):557-569. |
[6] | Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021[J]. Crit Care Med, 2021, 49(11):e1063-e1143. |
[7] |
Gouel-Cheron A, Swihart BJ, Warner S, et al. Epidemiology of ICU-onset bloodstream infection: Prevalence, pathogens, and risk factors among 150, 948 ICU patients at 85 U.S. hospitals[J]. Crit Care Med, 2022, 50(12):1725-1736.
doi: 10.1097/CCM.0000000000005662 pmid: 36190259 |
[8] |
Yahav D, Eliakim-Raz N, Leibovici L, et al. Bloodstream infections in older patients[J]. Virulence, 2016, 7(3):341-352.
doi: 10.1080/21505594.2015.1132142 pmid: 26684392 |
[9] | Moschou A, Ioannou P, Maraki S, et al. A prospective study of epidemiology characteristics and outcomes of bloodstream infections in older patients[J]. Australas J Ageing, 2021, 40(3):e182-e189. |
[10] |
Cuesta JM, Singer M. The stress response and critical illness: A review[J]. Crit Care Med, 2012, 40(12):3283-3289.
doi: 10.1097/CCM.0b013e31826567eb pmid: 22975887 |
[11] | Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine[J]. Intensive Care Med, 1996, 22(7):707-710. |
[12] | Tauber SC, Djukic M, Gossner J, et al. Sepsis-associated encephalopathy and septic encephalitis: An update[J]. Expert Rev Anti Infect Ther, 2021, 19(2):215-231. |
[13] | 王玲玲, 陈蕊, 董家辉, 等. mNUTRIC评分对老年脓毒症患者发生慢重症的预测价值测价值[J]. 中华急诊医学杂志, 2022, 31(1):73-77. |
[14] |
Marchick MR, Kline JA, Jones AE. The significance of non-sustained hypotension in emergency department patients with sepsis[J]. Intensive Care Med, 2009, 35(7):1261-1264.
doi: 10.1007/s00134-009-1448-x pmid: 19238354 |
[15] | 黄匀, 龚晨晨, 付建宇, 等. 重症监护病房血流感染预后危险因素分析[J]. 中华危重病急救医学, 2020, 32(12):1440-1444. |
[16] | 吴丽丽, 梁群, 曹雪丹. 中医药保护脓毒症肺血管内皮细胞损伤的机制研究进展[J]. 中国中医急症, 2021, 30(1):172-175. |
[17] | 陈瑞娟, 芮庆林, 郭涛, 等. 重症监护病房血流感染的临床特点和病原学分析[J]. 中国感染与化疗杂志, 2016, 16(6):673-679. |
[18] | 希仁娜依·木哈塔尔, 丁巍, 邬超, 等. 重症感染后白细胞降低30例临床分析[J]. 新疆医学, 2019, 49(2):119-122. |
[19] | 闫晶, 张珺, 张小彬, 等. 重症监护病房血流感染患者临床特点及预后影响因素分析[J]. 宁夏医学杂志, 2020, 42(4):322-325. |
[20] |
Wagenlehner FM, Lichtenstern C, Rolfes C, et al. Diagnosis and management for urosepsis[J]. Int J Urol, 2013, 20(10):963-970.
doi: 10.1111/iju.12200 pmid: 23714209 |
[21] | Buonacera A, Stancanelli B, Colaci M, et al. Neutrophil to lymphocyte ratio: An emerging marker of the relationships between the immune system and diseases[J]. Int J Mol Sci, 2022, 23(7):3636. |
[22] |
Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives[J]. Bratisl Lek Listy, 2021, 122(7):474-488.
doi: 10.4149/BLL_2021_078 pmid: 34161115 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||